Aoran Dong1,2,3,4,5,6, Jiali Zhang1,2,3,4,5,6, Xiaobin Chen7, Xiubao Ren1,2,3,4,5,6, Xinwei Zhang1,2,3,4,5,6. 1. Department of Biotherapy, Cancer Institute and Hospital, Tianjin Medical University, Tianjin 300060, China. 2. National Clinical Research Center for Cancer, Tianjin 300060, China. 3. Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. 4. Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China. 5. Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China. 6. Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. 7. Department of Oncology, the Affiliated Caner Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 45000, China.
Abstract
BACKGROUND: To investigate the roles of gastrin-releasing peptide (ProGRP) in the diagnosis of small cell lung cancer (SCLC). METHODS: We retrospectively analyzed data from 11,206 patients with clinical suspicion of lung cancer from January 1, 2015 to May 31, 2018. ProGRP and neuron-specific enolase (NSE) were detected in peripheral blood, and receiver operating characteristic curve (ROC) was used for analysis. RESULTS: ROC indicated that the cutoff values of ProGRP and NSE were 66 ng/L and 18 µg/L respectively, and the diagnosis efficacy of ProGRP was greater than that of NSE (sensitivity: 86.5% vs. 78.8%; specificity: 96.5% vs. 86.3%, respectively) in the diagnosis of SCLC. Moreover, the median level of ProGRP in SCLC increased with the accompanying stages (P<0.001). Further analysis showed that diagnostic efficacy can be improved by using different cutoff values in different stages, but not stage I and II. The cut-off values of ProGRP in the diagnosis of SCLC in stage I-II, III and IV were 56, 71 and 99 ng/L respectively. In addition, the sensitivity (96.6% vs. 95.8% and 98.3% vs. 94.8%) and concordance rate (χ2 =1,526.9 and 988.7, both P<0.001) of detecting SCLC was improved by using different cutoff values compared with the only criteria of ProGRP being ≥66 ng/L in stage III and IV, but not stage I-II. Additionally in stage III and IV, the concordance rates of ProGRP ≥71 ng/L and ProGRP ≥99 ng/L were also higher than ProGRP ≥300 ng/L (both P<0.001), which was conventionally indicated for SCLC. CONCLUSIONS: ProGRP has significantly higher sensitivity and specificity than NSE in the diagnosis of SCLC. Furthermore, special thresholds for every stage may be more reasonable for the diagnosis of SCLC.
BACKGROUND: To investigate the roles of gastrin-releasing peptide (ProGRP) in the diagnosis of small cell lung cancer (SCLC). METHODS: We retrospectively analyzed data from 11,206 patients with clinical suspicion of lung cancer from January 1, 2015 to May 31, 2018. ProGRP and neuron-specific enolase (NSE) were detected in peripheral blood, and receiver operating characteristic curve (ROC) was used for analysis. RESULTS: ROC indicated that the cutoff values of ProGRP and NSE were 66 ng/L and 18 µg/L respectively, and the diagnosis efficacy of ProGRP was greater than that of NSE (sensitivity: 86.5% vs. 78.8%; specificity: 96.5% vs. 86.3%, respectively) in the diagnosis of SCLC. Moreover, the median level of ProGRP in SCLC increased with the accompanying stages (P<0.001). Further analysis showed that diagnostic efficacy can be improved by using different cutoff values in different stages, but not stage I and II. The cut-off values of ProGRP in the diagnosis of SCLC in stage I-II, III and IV were 56, 71 and 99 ng/L respectively. In addition, the sensitivity (96.6% vs. 95.8% and 98.3% vs. 94.8%) and concordance rate (χ2 =1,526.9 and 988.7, both P<0.001) of detecting SCLC was improved by using different cutoff values compared with the only criteria of ProGRP being ≥66 ng/L in stage III and IV, but not stage I-II. Additionally in stage III and IV, the concordance rates of ProGRP ≥71 ng/L and ProGRP ≥99 ng/L were also higher than ProGRP ≥300 ng/L (both P<0.001), which was conventionally indicated for SCLC. CONCLUSIONS: ProGRP has significantly higher sensitivity and specificity than NSE in the diagnosis of SCLC. Furthermore, special thresholds for every stage may be more reasonable for the diagnosis of SCLC.
Entities:
Keywords:
ProGRP; Small cell lung cancer (SCLC); TNM staging
Authors: P Stieber; H Dienemann; A Schalhorn; U M Schmitt; J Reinmiedl; K Hofmann; K Yamaguchi Journal: Anticancer Res Date: 1999 Jul-Aug Impact factor: 2.480
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Chelsea Dumesny; Oneel Patel; Shamilah Lachal; Andrew S Giraud; Graham S Baldwin; Arthur Shulkes Journal: Endocrinology Date: 2005-10-13 Impact factor: 4.736
Authors: Ralph Meuwissen; Sabine C Linn; R Ilona Linnoila; John Zevenhoven; Wolter J Mooi; Anton Berns Journal: Cancer Cell Date: 2003-09 Impact factor: 31.743
Authors: N V Lyubimova; A E Kuz'minov; A A Markovich; A V Lebedeva; Yu S Timofeev; I S Stilidi; N E Kushlinskii Journal: Bull Exp Biol Med Date: 2022-06-23 Impact factor: 0.804